80 results
8-K
EX-1.1
PROK
ProKidney Corp - Ordinary Shares
13 Jun 24
ProKidney Announces Pricing of its Upsized $130 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering
9:06am
of any litigation, if such settlement is effected with the written consent of the Company), insofar as such loss, claim, damage, liability or expense … federal or state statutory law or regulation, or at common law or otherwise (including in settlement of any litigation, if such settlement is effected
8-K
EX-5.1
PROK
ProKidney Corp - Ordinary Shares
13 Jun 24
ProKidney Announces Pricing of its Upsized $130 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering
9:06am
award costs in litigation in accordance with contractual provisions in this regard; and
the effectiveness of terms in the Documents excusing any party
8-K
EX-10.1
PROK
ProKidney Corp - Ordinary Shares
13 Jun 24
ProKidney Announces Pricing of its Upsized $130 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering
9:06am
otherwise govern under applicable principles of conflicts of laws thereof) as to all matters (including any action, suit, litigation, arbitration
424B5
PROK
ProKidney Corp - Ordinary Shares
13 Jun 24
Prospectus supplement for primary offering
7:00am
litigation due to share volatility.
Our share price may fluctuate for many reasons, including as a result of public announcements regarding the progress … experienced significant price and trading volatility have occasionally brought securities class action litigation against the companies that issued
424B5
PROK
ProKidney Corp - Ordinary Shares
10 Jun 24
Prospectus supplement for primary offering
5:13pm
class action litigation due to share volatility.
Our share price may fluctuate for many reasons, including as a result of public announcements regarding … which have experienced significant price and trading volatility have occasionally brought securities class action litigation against the companies
8-K
pw5cbdm523ri4au
10 Jun 24
ProKidney Announces Positive Interim REGEN-007 Phase 2 Trial Data and Provides Clinical and Operational Updates
8:00am
8-K
EX-99.2
agvdq5borewn1
10 Jun 24
ProKidney Announces Positive Interim REGEN-007 Phase 2 Trial Data and Provides Clinical and Operational Updates
8:00am
8-K
EX-99.1
sirnw153l97a
10 Jun 24
ProKidney Announces Positive Interim REGEN-007 Phase 2 Trial Data and Provides Clinical and Operational Updates
8:00am
8-K
EX-99.1
nudlp0
29 May 24
RMCL-002 Final Analysis Developing Solutions for Dialysis Prevention May 2024
7:04am
8-K
EX-99.1
9y952mov2xvs3za
10 May 24
ProKidney Reports Business Updates and First Quarter 2024 Financial Results
7:05am
8-K
EX-99.1
nyrrn
25 Mar 24
ProKidney Announces Key Leadership Appointments Strengthening Clinical and Technical Operations
4:07pm
8-K
EX-99.1
hojizyq
21 Mar 24
ProKidney Reports Full Year 2023 Financial Results and Recent Corporate Highlights
8:00pm
8-K
EX-99.1
mnkdzrrm9q2pq7fdud10
26 Jan 24
Regulation FD Disclosure
12:00am
8-K
EX-1.1
fj7tl4
19 Jan 24
Entry into a Material Definitive Agreement
4:19pm
8-K
EX-5.1
ylwooadhum 9pi3qis
19 Jan 24
Entry into a Material Definitive Agreement
4:19pm
424B5
kdbtri7igmiy ow
19 Jan 24
Prospectus supplement for primary offering
4:16pm
S-3
EX-5.1
f39j5tx06m
22 Nov 23
Shelf registration
9:22am